The opportunity to use recently developed AMPK activators for the treatment of myeloid malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and chronic myelomonocytic leukemia (CMML) will also be addressed. The gene discussed is PRKAA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.